AstraZeneca Names Shanghai Site as Initial Base for New Innovation Centre China

AstraZeneca Names Shanghai Site as Initial Base for New Innovation Centre China

AstraZeneca today announced Shanghai's Zhangjiang Hi-Tech Park as the initial
base for its new Innovation Centre China (ICC). 

The ICC, announced in May 2006 as part of a larger $100 million R&D investment
package, is the primary focus of AstraZeneca's latest investment in China.  The
Centre will focus on the benefit and value of innovative medicines for Chinese
patients, initially concentrating on cancer through the development of knowledge
about Chinese patients, biomarkers and genetics.  The start of construction work
at the site is an important milestone in establishing a dedicated AstraZeneca
research presence in China and the company's ambitions of having a strong R&D
presence in the region. 

Jan Lundberg, Executive Vice-President of Discovery at AstraZeneca, said: “This
is an important step forward in a high priority project which promises to hold
great potential to advance our understanding of a disease which has such
devastating consequences.  It will be an integral part of our global R&D
activity aimed at ensuring that the right patients are treated with our oncology
drugs and will take advantage of the excellent science base in Shanghai where
there is a burgeoning biotech industry. “This milestone is also another powerful
example of our of policy of being ‘In China for China'.”

James Ward-Lilley, President of AstraZeneca China, said: “As the leading ethical
pharmaceutical company in the country we fully support China's national focus on
innovation by substantially increasing our R&D investment, both in financial
terms and in terms of scientific collaboration.

“We believe the research work at ICC will address the area of significant unmet
need, and will bring novel therapy to Chinese patients.“

The facility will open in mid-2007 and provide a base to build capabilities and
skills in China prior to the establishment of a permanent state-of-the-art site.
 AstraZeneca has already initiated a comprehensive search for a permanent
location for the ICC.

“Zhangjiang Hi-Tech Park offers us great facilities and an ideal base from which
to intensify recruitment of the 70-plus scientists and physicians specialising
in translational science who will progress the ICC's early and later stage
research projects.  Initially these projects will be specific to cancer, a major
cause of death in China,” said Xiaolin Zhang, Head of the ICC.

Recruitment of these scientists and physicians is already underway.  They will
join the 2,900 already employed by AstraZeneca in China, a leading multinational
company there with a network of more than 20 marketing and sales offices; a
manufacturing site at Wuxi, Jiangsu Province inaugurated in 2001; and clinical
research facilities.  AstraZeneca was the first multinational pharmaceutical
company to include China as an area for large-scale international multi-centre
trials and establish a local clinical research centre.  The company has long
been dedicated to strengthening collaborations with local academic and medical
institutions.

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in research,
development, manufacturing and marketing of prescription pharmaceuticals and
supplier for healthcare services.  AstraZeneca is one of the world's leading
pharmaceutical companies with healthcare sales of US  $26.47  billion and is a
leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology
and infection product sales.  AstraZeneca is listed in the Dow Jones
Sustainability Index (Global) as well as the FTSE4Good Index.

For more information about AstraZeneca in China please visit:
www.astrazeneca.com.cn.  Broadcast footage of AstraZeneca China is available on
www.thenewsmarket.com/astrazeneca 

Media Enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034 
Steve Brown, Tel: +44 (0) 207 304 5033 

AstraZeneca China: 
May Jia, Tel: +86 21 5256 4555 X 1500
Zhou Yi, Tel: +86 21 5256 4555 X 1503

Notes to News Editors:
The AstraZeneca Innovation Centre China (ICC) will concentrate its initial focus
on translational medicine in cancer.  In broad terms, translational medicine
(translational science) is defined as the application of basic scientific
research for the direct benefit of patients.  

At the ICC, researchers will work on the identification, development, and
validation of new biomarkers. Activities at the ICC will include analysis of
human biological samples from clinical and experimental settings. The ICC will
feature state-of-the-art biomedical informatics capabilities and advanced IS/IT
support. The Centre will employ pre-clinical scientists and physicians who will
progress both early and later-stage drug research projects.